2012•Nuclear Medicine ReviewOpen access

Clinical applications of 18F fluoro-2-deoxy-D-glucose (FDG) positron emission tomography- computed tomography (PET/CT)

Lucia Zanoni, Abdulaziz Al‐Sugair, Stefano Fanti

Abstract

Positron emission computed tomography (PET) is a functional diagnostic imaging modality. Coupled with computed tomography (CT), it has a high accuracy, adding morphological informations. F-18 fluoro-2-deoxy-D-glucose (FDG), an analogue of glucose, is the most commonly used radiotracer. Its uptake reflects glucose metabolism in the cells which is increased several times in malignant tumors. However FDG is not a cancer specific agent and its uptake has been described in a number of non-neoplastic inflammatory lesions. The aim of our paper is to summarize its major indications in the clinical practice.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Positron emission tomography, Positron Emission Tomography-Computed Tomography, Positron emission, Nuclear medicine, Computed tomography, Medicine, Brain positron emission tomography, Tomography